Artificial Intelligence continues to be a significant driver for advancing healthcare, and understanding the microbiome will be pivotal to that transformation. Adnexus is building on the consortium to utilize AI to assess the effects of nutrition, genetics, and the human microbiome on diseases. This is a part of the Company’s long-term strategy to enter the personalized medicine market and build a robust Intellectual Property portfolio covering its discoveries.
This focus includes:
- Building prediction models for Neurodegenerative Diseases
- Identifying biomarkers for Chronic Medical Diseases and Neurodegenerative Diseases.
- Identifying novel targets and clear intervention strategies for Neurodegenerative diseases and Chronic medical diseases
